> ## Content Index
> Fetch the complete content index at: https://www.moatmarginresearch.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Gland Pharma Moat Analysis: Score & Risks
- URL: https://www.moatmarginresearch.com/gland-pharma-moat/
- Published: 2026-08-02T13:11:50.000Z
- Updated: 2026-08-22T05:14:29.000Z
- Author: A K Karthikeyan
- Tags: First-pass note, Coverage

Moat Note · First-pass

## Gland Pharma Ltd.

A first-pass moat teardown of Gland Pharma Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.

**Moat & Margin**2 Aug 2026 First-pass · \~4 min

5.37 / 10

NARROWRegulated-scale

First-pass narrow read — primary edge in Intangible Assets. Provisional, single-pass evidence.

Provisional score · subject to modification based on new evidence

Gland Pharma Ltd. scores **5.37** on MoatSCORE 6.0 — a narrow moat in Pharma. This is a **first-pass note**: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.

The teardown 

## Seven dimensions of moat

Ordered by contribution. Each dimension carries a verified filing quote, graded **\[M\]** mechanism or **\[O\]** outcome.

D5Intangible Assets6.5

M · Mechanism✓ Verified verbatim

“Acquiring Cenexi gives us access to knowhow and development capabilities in sterile forms, including for ophthalmic gel, needleless injectors and hormones.”

**Gland Pharma Ltd.** · Annual Report · p.24

D3Cost Advantage6

M · Mechanism✓ Verified verbatim

“New high-capacity ampoule line is being added, with a capacity of 30 million by 2027, strengthening the position of the site on the market as the largest ampoule manufacturing site in Europe”

**Gland Pharma Ltd.** · Investor Presentation · p.13

D4Price Discretion5

M · Mechanism✓ Verified verbatim

“we're trying to grow substantially, but not at kind of products, more complex specialty kind of products”

**Gland Pharma Ltd.** · Earnings Call · p.11

D1Network Effects4.8

No narrative receipt surfaced — this dimension is scored on the quantitative record.

D2Switching Costs4.5

M · Mechanism✓ Verified verbatim

“Our B2B business model allows us to leverage our relationship with customers to efficiently reach end-users.”

**Gland Pharma Ltd.** · Annual Report · p.26

D6Efficient Scale4.5

No narrative receipt surfaced — this dimension is scored on the quantitative record.

D7Counter-PositioningExcluded—

Excluded for this archetype.

D8Ungoverned RiskUnscored · Layer 2.5

D8 rating: **ADEQUATE**. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.

The barrier gate 

## The barrier gate — first-pass

Replication — can a rival copy it?6.5

How hard it is for a rival to copy the edge (first-pass estimate).

Bypass — can a rival route around it?6.0

How easily a rival can route around the edge (first-pass estimate).

Effective barrier 6.0 — clears the gate. First-pass estimate.

What would change our mind

1. **Deep two-pass review.** This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
2. **The barrier gate.** A firmer replication or bypass estimate is the most likely thing to shift the band.
3. **Adverse events.** Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.

First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.

**Where this note fits.** This company is one of **113 Indian companies** we have scored for moat durability — 88 narrow, 25 narrow-trending-wide, none wide. The full ranked read: [Wide-Moat Stocks in India: We Scored 113 Companies and Found None](https://www.moatmarginresearch.com/wide-moat-stocks-india/). Every score, dimension by dimension, is free in the [Moat Screener](https://www.moatmarginresearch.com/moat-screener/).